Why are we still overlooking adherence in clinical trials? A call to extend medication adherence-enhancing interventions and monitoring beyond real-world practice

We read with great interest the editorial by Eriksson and Midlöv, which rightly underscores the persistent challenge of medication adherence and the potential impact of effective medication adherence-enhancing interventions (MAEIs) on population health, healthcare costs and clinical outcomes.1 Despite decades of awareness and growing technological promise, the translation of MAEIs into scalable, reimbursable and evidence-based practice remains relatively limited.